(VELA) Study of BLU-222 in Advanced Solid Tumors
Terminated · Phase 1 · NCT05252416
Conditions: Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
At a glance
- Research payments reported, 2025
- $919,074
- U.S. investigators named
- 19
- Sites paid
- 23
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Blueprint Medicines Corporation
- Tested
- BLU-222 (drug), Carboplatin (drug), Ribociclib (drug), Fulvestrant (drug)
- Dates
- Started 2022-04-07; completion 2025-07-04
- Results posted
- Not yet
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
From ClinicalTrials.gov, last updated 2025-11-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $919,074 in research payments for this study in 2025 (140 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael J. Birrer, M.D. PH.D. Hematology & Oncology · Birmingham, AL
- Pamela N. Munster, MD Medical Oncology · Stanford, CA
- Melinda L. Telli, MD Medical Oncology · Stanford, CA
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- Dejan Juric, M.D. Medical Oncology · Boston, MA
- Ursula A. Matulonis, MD Medical Oncology · Boston, MA
- Stephanie L. Gaillard, MD, PHD Medical Oncology · Baltimore, MD
- Eugenia Girda, M.D. Gynecologic Oncology · New Brunswick, NJ
- Yara G. Abdou, MD Hematology & Oncology · Albuquerque, NM
- Komal Jhaveri Medical Oncology · New York, NY
- Julia E. Mcguinness, M.D. Medical Oncology · New York, NY
- Nicole Nevadunsky Specialist · Bronx, NY
- Debra L. Richardson, M.D. Gynecologic Oncology · Oklahoma City, OK
- Julia Foldi, M.D. Hematology & Oncology · Pittsburgh, PA
- Melissa Mcshane, M.D. Medical Oncology · Philadelphia, PA
- Laura C. Kennedy, M.D,, PH.D Hematology & Oncology · Nashville, TN
- Timothy A. Yap, MD Medical Oncology · Houston, TX
- Theresa L. Werner, MD Hematology & Oncology · Salt Lake City, UT
- Linda R. Duska, MD Gynecologic Oncology · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $189,773
- University of Virginia Medical Center, VA $150,439
- Vanderbilt University Medical Center, TN $132,556
- Dana Farber PArtners Cancer Care Inc $85,151
- University of Utah Hospital and Clinics, UT $61,999
- Memorial Sloan Kettering Cancer Center Admin Office $61,751
- The Trustees of Columbia University $52,636
- University of Illinois Hospital and Clinics, IL $47,131
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $37,902
- Johns Hopkins University $21,302
- Sarah Cannon Research Institute $17,554
- University of Pittsburgh Cancer Institute Cancer Services $15,000
- The Research Institute of Fox Chase Cancer Center $9,400
- Rutgers the State University of New Jersey $7,838
- University of California Davis Medical Center, CA $7,542
- Nursing Ce Trust Fund $6,915
- Sarah Cannon Research Institution Llc $5,000
- Mt Sinai Biomedical Resarch Alliance of New York $2,800
- Sarah Cannon Research Inst Llc $2,500
- Institute for Cancer Research $2,293
- University of Arkansas Medical Sciences, AR $1,071
- Stanford University Care Fund Ghghm $444
- The University of North Carolina at Chapel Hill Unc Department of Pediatrics Attn Colleen Williams 3 $77
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.